2023-11-28 17:00:00
The Parisian biotech Acticor has just carried out a capital increase for a total amount of approximately 2.6 million euros, via the issue of 850,360 shares, at a price of €3 per share.
Thanks to this sum, Acticor sees its financial visibility extended until May 2024. The biotech will however have to continue to seek other financing, up to €8 million to meet its obligations over the next twelve months.
VOS INDICES
source
“We have also received valuable support from institutional investors as well as many retail investors, through the PrimaryBid platform. (…) Rest assured that we will continue to pursue with determination our mission aimed at bringing to market an innovative drug for the treatment of cardiovascular emergencies”declared Gilles Avenard, general manager of Acticor Biotech.
Specializing in cardiovascular diseases, Acticor is developing a drug candidate first-in-class for the emergency treatment of stroke, glenzocimab. The biotech intends to use the funds raised to finance the phase II/III trial of this compound, the results of which are expected in the second quarter of 2024.
Selected for you
1701283375
#Cardiovascular #Acticor #raises #million
